RA Capital Management’s SAB Biotherapeutics SABS Stock Holding History

RA Capital Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.2M	Hold	4,401,500	–	–	0.15%	69
2026 Q1	$16.9M	Hold	4,401,500	–	–	0.18%	63
2025 Q4	$16.5M	Hold	4,401,500	–	–	0.17%	53
2025 Q3	$8.85M	Buy	+4,401,500	New	+$9.95M	0.11%	53
2024 Q1	–	Sell	-237,408	Closed	-$1.63M	–	78
2023 Q4	$1.63M	Buy	+237,408	New	+$1.99M	0.03%	61

Other funds holding SABS

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

RA Capital Management's SABS Position: Q2 2026 in Review

RA Capital Management held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 4,401,500 shares worth $17.2M. The position accounts for 0.15% of the portfolio, ranked #69.

RA Capital Management first reported a position in SABS in Q4 2023 and has held it in 5 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

RA Capital Management held 4,401,500 shares of SAB Biotherapeutics worth $17.2M as of Q2 2026.
RA Capital Management left its SAB Biotherapeutics share count unchanged in Q2 2026.
SAB Biotherapeutics made up 0.15% of RA Capital Management's portfolio in Q2 2026, its #69 holding.
RA Capital Management first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 5 quarters since.
87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.